Phase 3 Clinical Trials With Primary Completion Dates in July 2021
This is a list of Phase 3 trials with primary completion dates in July 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ADIL||Adial Pharmaceuticals, Inc.||2021-07-01||Phase 3||NCT04101227||Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms|
|BBI||Brickell Biotech, Inc.||2021-07-01||Phase 3||NCT03836287||Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)|
|BFRA||Biofrontera AG||2021-07-01||Phase 3||NCT03573401||Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).|
|CURR||CURE Pharmaceutical Holding Corp.||2021-07-01||Phase 3||NCT04668950||Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)|
|HLUYY||H. Lundbeck A/S||2021-07-01||Phase 3||NCT04418765||A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive Treatments|
|HRTX||Heron Therapeutics, Inc.||2021-07-01||Phase 3||NCT03907176||Herniorrhaphy Study for Opioid Elimination|
|ICPT||Intercept Pharmaceuticals, Inc.||2021-07-01||Phase 3||NCT03439254||Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis|
|LNTH||Lantheus Holdings, Inc.||2021-07-01||Phase 3||NCT02764801||Contrast-enhanced Ultrasound Evaluation of Chemoembolization|
|MEDD||Medical Imaging Corp.||2021-07-01||Phase 3||NCT02764801||Contrast-enhanced Ultrasound Evaluation of Chemoembolization|
|MIRM||Mirum Pharmaceuticals, Inc.||2021-07-01||Phase 3||NCT03905330||A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)|